

# UNITING IN THE FIGHT AGAINST CANCER

## CANCER IS AMONG THE LEADING CAUSES OF DEATH WORLDWIDE




**10 million people die** from cancer every year



**Yet 30-50% of** all cancers are preventable<sup>1</sup>

## Most Newly Diagnosed Cancers in 2020<sup>2</sup>



<b>2.3M</b>	Breast
<b>2.2M</b>	Lung
<b>1.9M</b>	Colon & Rectum
<b>1.4M</b>	Prostate
<b>1.2M</b>	Skin
<b>1.1M</b>	Stomach

## THE COST OF CANCER AFFECTS US ALL<sup>3</sup>

The economic impact of cancer is significant and increasing.

The total annual economic cost of cancer is estimated at **USD 1.16 trillion**.

Investing **USD 11.4 billion** in research and prevention strategies could save up to **3.7 million** lives and **USD 100 billion** in treatment costs each year.



Premature death



Productivity loss




Inflating healthcare costs



Household financial burdens



Disability




## Impact of COVID-19 on Research and Care

As the impact of the pandemic continues to unfold, oncologists are reporting that global caseloads are 26-51% lower than pre-COVID-19 levels.<sup>4</sup> The disruption to care may be putting millions at greater risk for delayed diagnosis and treatment.

Despite the COVID-19 delays, new clinical trials are reaching a new high. Paused trials are restarting faster, and patients are enrolling at increasing rates.

## Oncology Trials Stopped Due to COVID-19<sup>5</sup>


(by year started)




## CREATING A FUTURE WITHOUT CANCER

Considerable advancements in treatments and diagnostic tools have reduced cancer rates and improved cancer survival in the US.<sup>6</sup>

However, continued investment and research are needed to meet numerous unmet patient needs and to advance knowledge in cancer.



## HOW MEDIDATA IMPROVES ONCOLOGY TRIALS



Medidata's ongoing commitment to fighting cancer translates into our continuous innovation in clinical trial solutions.

In today's complex world of precision medicine, our unified platform, the Medidata Clinical Cloud™, enables clinical trials to run more efficiently, deliver higher quality data, and ensure safer experiences and outcomes for patients.

## MEDIDATA'S EXTENSIVE EXPERIENCE, TECHNOLOGY, DATA, AND EXPERTISE IN ONCOLOGY TRIALS

Medidata solutions have been involved in the development of **75% of all FDA oncology novel drug approvals since 2015**

**5,100+**

Oncology studies

**500**

Unique sponsors with Oncology trials

**370K+**

Sites set up to conduct Oncology trials

**1M+**

Enrolled Oncology patients

<sup>1</sup> <https://www.worldcancerday.org/what-cancer>

<sup>2</sup> <https://www.who.int/news-room/fact-sheets/detail/cancer>

<sup>3</sup> <https://www.who.int/news-room/fact-sheets/detail/cancer>

<sup>4</sup> IQVIA Impact of COVID-19 on the Treatment of Cancer Reports, Feb 2021 — US, EU4 and UK, and Japan

<sup>5</sup> <https://www.cancerresearch.org/en-us/blog/may-2021/covid-19-impact-oncology-clinical-trials-2020-2021>

<sup>6</sup> <https://www.cancer.org/latest-news/facts-and-figures-2022.html>

<sup>7</sup> <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2021>